X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (549) 549
Conference Proceeding (236) 236
Book Review (26) 26
Publication (21) 21
Patent (14) 14
Book / eBook (8) 8
Book Chapter (5) 5
Magazine Article (4) 4
Government Document (2) 2
Data Set (1) 1
Dissertation (1) 1
Journal / eJournal (1) 1
Report (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
dermatology (243) 243
index medicus (186) 186
humans (184) 184
oncology (139) 139
male (101) 101
female (99) 99
melanoma (90) 90
middle aged (87) 87
aged (71) 71
adult (69) 69
immunology (64) 64
melanoma - drug therapy (52) 52
cancer (50) 50
analysis (46) 46
mineralogy (45) 45
skin neoplasms - pathology (43) 43
melanoma - pathology (42) 42
skin neoplasms - drug therapy (42) 42
care and treatment (41) 41
metastasis (40) 40
metastatic melanoma (40) 40
aged, 80 and over (39) 39
skin (35) 35
skin cancer (34) 34
ipilimumab (33) 33
cell biology (31) 31
immunotherapy (31) 31
prognosis (31) 31
treatment outcome (31) 31
histamine (30) 30
survival (30) 30
therapy (29) 29
tumors (27) 27
antineoplastic agents - therapeutic use (26) 26
geochemistry & geophysics (26) 26
retrospective studies (26) 26
geology (25) 25
malignant-melanoma (24) 24
medicine & public health (24) 24
melanoma - genetics (24) 24
dendritic cells (23) 23
melanoma - secondary (23) 23
allergy (22) 22
medicine, research & experimental (22) 22
young adult (22) 22
melanoma - mortality (21) 21
metastases (21) 21
minerals (21) 21
antineoplastic agents - adverse effects (20) 20
cutaneous melanoma (20) 20
mutation (20) 20
nivolumab (20) 20
open-label (20) 20
abridged index medicus (19) 19
atopic-dermatitis (19) 19
patients (19) 19
skin neoplasms - therapy (19) 19
neoplasm staging (18) 18
animals (17) 17
disease-free survival (17) 17
h-4 receptor (17) 17
hematology, oncology and palliative medicine (17) 17
skin neoplasms - mortality (17) 17
adolescent (16) 16
biopsy (16) 16
braf (16) 16
lymphatic metastasis (16) 16
medical colleges (16) 16
melanoma - therapy (16) 16
mice (16) 16
proto-oncogene proteins b-raf - antagonists & inhibitors (16) 16
sentinel lymph node biopsy (16) 16
vemurafenib (16) 16
clinical trials (15) 15
expression (15) 15
management (15) 15
mining & mineral processing (15) 15
pembrolizumab (15) 15
radiotherapy (15) 15
receptors, histamine h4 (15) 15
antineoplastic agents - administration & dosage (14) 14
dendritic cells - immunology (14) 14
kaplan-meier estimate (14) 14
medical research (14) 14
mineralization (14) 14
skin neoplasms - genetics (14) 14
trial (14) 14
allergology (13) 13
antibodies, monoclonal - adverse effects (13) 13
chemotherapy (13) 13
geochemistry (13) 13
geosciences, multidisciplinary (13) 13
mutations (13) 13
recurrence (13) 13
antibodies, monoclonal - therapeutic use (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
dabrafenib (12) 12
histamine h4 receptor (12) 12
proctology (12) 12
protein kinase inhibitors - therapeutic use (12) 12
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 6, pp. 716 - 728
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2013, Volume 8, Issue 1, pp. e53745 - e53745
Background: Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces... 
REGRESSION | TRIAL | INDUCED SARCOIDOSIS | CTLA-4 BLOCKADE | AUTOIMMUNITY | SAFETY | MULTIDISCIPLINARY SCIENCES | MONOCLONAL-ANTIBODY | PATIENT | HYPOPHYSITIS | CANCER | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Neoplasm Metastasis | Liver - drug effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Endocrine System - drug effects | Adult | Female | Retrospective Studies | Antibodies, Monoclonal - immunology | Kidney - drug effects | Antineoplastic Agents - immunology | Pancreas - drug effects | Gastrointestinal Tract - drug effects | Melanoma - pathology | CTLA-4 Antigen - immunology | Nervous System - drug effects | Melanoma - drug therapy | Respiratory System - drug effects | Aged | Skin - drug effects | Antimitotic agents | Antigens | Care and treatment | Algorithms | Lymphocytes | Melanoma | Skin | Metastasis | Antineoplastic agents | Skin cancer | Cancer | Aseptic meningitis | Guillain-Barre syndrome | Exanthema | Central nervous system | Blocking antibodies | Cytotoxicity | Oncology | Lymphocytes T | Metastases | CTLA-4 protein | Intestine | Gastroenterology | Meningitis | Internal medicine | Hematology | Sarcoidosis | Dermatology | Management | Regression analysis | Patients | Eosinophilia | Morbidity | Inflammatory bowel disease | Pathology | Side effects | Hospitals | Perforations | Medical prognosis | Antitumor activity | Autoimmune diseases | Endocrinology | Index Medicus
Journal Article
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, ISSN 1610-0379, 08/2017, Volume 15, pp. 52 - 53
Conference Proceeding
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 60, pp. 210 - 225
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016, Volume 75, Issue 1, pp. 113 - 125.e5
Background The hedgehog pathway inhibitor sonidegib demonstrated meaningful tumor shrinkage in more than 90% of patients with locally advanced basal cell... 
Dermatology | Basal Cell Carcinoma Outcomes with LDE225 Treatment study | hedgehog pathway inhibitor | sonidegib | locally advanced basal cell carcinoma | metastatic basal cell carcinoma | advanced basal cell carcinoma | Locally advanced basal cell carcinoma | Advanced basal cell carcinoma | Metastatic basal cell carcinoma | Sonidegib | Hedgehog pathway inhibitor | HEDGEHOG PATHWAY | MULTICENTER | VISMODEGIB | MANAGEMENT | EFFICACY | GUIDELINES | OPEN-LABEL | DERMATOLOGY | DOSE-ESCALATION | UPDATE | INHIBITOR | Skin Neoplasms - drug therapy | Humans | Middle Aged | Carcinoma, Basal Cell - secondary | Biphenyl Compounds - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Biphenyl Compounds - therapeutic use | Young Adult | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Smoothened Receptor - antagonists & inhibitors | Pyridines - therapeutic use | Skin Neoplasms - pathology | Pyridines - administration & dosage | Double-Blind Method | Survival Rate | Disease Progression | Biphenyl Compounds - administration & dosage | Carcinoma, Basal Cell - drug therapy | Aged | Medical research | Care and treatment | Basal cell carcinoma | Analysis | Patient outcomes | Corn | Medicine, Experimental | Skin | Metastasis | Drug therapy | Cancer | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 733 - 740
Summary Background Patients with metastatic melanoma, 50% of whose tumours harbour a BRAF mutation, have a poor prognosis. Selumetinib, a MEK1/2 inhibitor, has... 
Hematology, Oncology and Palliative Medicine | CELL LUNG-CANCER | TRIAL | KINASE KINASE-1/2 INHIBITOR | MULTICENTER | ONCOLOGY | ORAL MEK INHIBITOR | IMPROVED SURVIVAL | INHIBITOR AZD6244 ARRY-142886 | OPEN-LABEL | MUTATIONS | VEMURAFENIB | Dacarbazine - adverse effects | Skin Neoplasms - drug therapy | Humans | Middle Aged | Male | Antineoplastic Agents, Alkylating - administration & dosage | Skin Neoplasms - enzymology | Benzimidazoles - administration & dosage | Time Factors | DNA Mutational Analysis | Brazil | Proto-Oncogene Proteins B-raf - metabolism | Dacarbazine - administration & dosage | Genetic Predisposition to Disease | Neoplasms, Unknown Primary - genetics | Europe | Logistic Models | Antineoplastic Agents, Alkylating - therapeutic use | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Mutation | Antineoplastic Agents, Alkylating - adverse effects | Melanoma - mortality | Dacarbazine - therapeutic use | United States | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Melanoma - enzymology | Neoplasms, Unknown Primary - enzymology | Melanoma - genetics | Skin Neoplasms - mortality | Adult | Female | Skin Neoplasms - pathology | Neoplasms, Unknown Primary - drug therapy | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Neoplasms, Unknown Primary - mortality | Melanoma - secondary | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Aged | Neoplasms, Unknown Primary - pathology | Care and treatment | Chemotherapy | Gene mutations | Analysis | Melanoma | Metastasis | Cancer | Index Medicus
Journal Article
by Sosman, J and Sznol, M and McDermott, D. F and Carvajal, R and Lawrence, D. P and Topalian, S. L and Wigginton, J. M and Kollia, G and Gupta, A and Hodi, F. S and Gutzmer, R and Rivoltini, L and Levchenko, E and Testori, A and Utikal, J and Ascierto, P. A and Salaun, B and Vanhoutte, N and Gillet, M and Brichard, V and Weiss, G. J and Oro, A and Chang, A. L. S and Solomon, J. A and LoRusso, P. M and Hamid, O and Chen, D. M and McKenna, E and Feng, S and Hainsworth, J. D and Sekulic, A and Migden, M. R and Lewis, K and Yoo, S and Dirix, L and Hou, J and Yue, H and Hauschild, A and Rendleman, J and Shang, S and Brocia, C and Ma, M and Shapiro, R and Berman, R and Pavlick, A and Shao, Y and Osman, I and Kirchhoff, T and Bol, K and Aarntzen, E and Gerritsen, W. R and Schreibelt, G and Jacobs, J and Lesterhuis, W. J and van Rossum, M and Punt, C. J. A and Figdor, C and De Vries, J and Thompson, J and Gordon, M and Wolchok, J and Rojas, P and Schwartz, J and Bedikian, A and Lebbe, C and Weber, J. S and Maio, M and Neyns, B and Harmankaya, K and Chin, K and McDowell, D. O and Cykowski, L and McHenry, M. B and Wolchok, J. D and Di Giacomo, A. M and Calabro, L and Danielli, R and Pesce, I and Fonsatti, E and Bertocci, E and Giannarelli, D and Biagioli, M and Altomonte, M and Colombino, M and Sini, M and De Giorgi, V and Lissia, A and Massi, D and Rubino, C and Cossu, A and Ayala, F and Palmieri, G and Costa, E. F. D and Lourenco, G. J and Oliveira, C and Rinck-Junior, J. A and Moraes, A. M and Nogueira, G. A. S and Lima, C. S. P and Mandala, M and ... and on behalf of Phase 3 Principal Investigators
Annals of Oncology, ISSN 0923-7534, 09/2012, Volume 23, Issue suppl 9, pp. ix361 - ix375
Journal Article
2016, ISBN 3319246224, 132
This book offers fresh insights into how companies can engage with, and make use of, the modern metropolis. Based on actor-network theory and the... 
Management science | Industries | Knowledge management | Creative ability in business
eBook
Annals of Oncology, ISSN 0923-7534, 09/2014, Volume 25, Issue suppl_4
Abstract Aim: The BOLT phase 2 study, comparing 2 doses of sonidegib, a hedgehog pathway inhibitor (HhPI), in pts with advanced BCC (aBCC; NCT01327053), met... 
Journal Article
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, ISSN 1610-0379, 08/2013, Volume 11, Issue s6, pp. 1 - 116
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 19, pp. 1789 - 1801
A blinded trial involving patients with resected stage III melanoma showed that adjuvant pembrolizumab every 3 weeks for a year was associated with a 1-year... 
HIGH-RISK MELANOMA | SURVIVAL | MEDICINE, GENERAL & INTERNAL | ANTI-PD-1 THERAPY | EORTC 18952 | TUMOR BURDEN | CUTANEOUS MELANOMA | PHASE-3 TRIAL | PEGYLATED INTERFERON-ALPHA-2B | NODE-POSITIVE MELANOMA | IPILIMUMAB | Skin Neoplasms - drug therapy | Humans | Middle Aged | Male | Adjuvants, Immunologic - adverse effects | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Survival Rate | Disease-Free Survival | B7-H1 Antigen - antagonists & inhibitors | Melanoma - drug therapy | Intention to Treat Analysis | Quality of Life | Aged | B7-H1 Antigen - analysis | Infusions, Intravenous | Melanoma - surgery | Neoplasm Staging | Melanoma - mortality | Diagnosis | Drug therapy | Patients | Health aspects | Melanoma | Medical research | Lymphatic system | Risk groups | PD-1 protein | Committees | Metastasis | Survival | Skin cancer | Pembrolizumab | Hospitals | Motivation | PD-L1 protein | Myositis | Death | Mutation | Tumors | Cancer | Index Medicus | Abridged Index Medicus | Placebos | Placebos (Medicine) | Adjuvant treatment of cancer | Tractament adjuvant del càncer
Journal Article
Journal of the European Academy of Dermatology and Venereology, ISSN 0926-9959, 03/2018, Volume 32, Issue 3, pp. 372 - 381
BackgroundPatients with locally advanced basal cell carcinoma (laBCC) or metastatic BCC (mBCC), two difficult-to-treat populations, have had limited treatment... 
GDC-0449 | HEDGEHOG PATHWAY | MULTICENTER | VISMODEGIB | ORAL INHIBITOR | LDE225 | OPEN-LABEL | DERMATOLOGY | Care and treatment | Basal cell carcinoma | Metastasis | Analysis | Index Medicus | Original and Short Reports | Original
Journal Article
by Schmidt, Manfred and Verhoeyen, Els and Gobbo, Emilie and Divers, Dominique and Oudrhiri, Noufissa and Griscelli, Frank and Bennaceur-Griscelli, Annelise and Klatzmann, David and Anguela, Xavier M and Sharma, Rajiv and Sharma, Rajiv and Li, Hojun and Li, Hojun and Haurigot, Virginia and Haurigot, Virginia and Haurigot, Virginia and Bhagwat, Anand and Bhagwat, Anand and Davidson, Robert and Davidson, Robert and Zhou, Shangzhen and Zhou, Shangzhen and Zhou, Shangzhen and Doyon, Yannick and Gregory, Philip D and Gregory, Philip D and Gregory, Philip D and Holmes, Michael C and Holmes, Michael C and Holmes, Michael C and High, Katherine A and Carbonaro, Denise and Shaw, Kit and Jin, Xiangyang and Geiger, Sabine and Mishra, Suparna and Cooper, Aaron and DeOliveira, Satiro and Sokolic, Rob and Candotti, Fabio and Carmo, Marlene and Arumugam, Paritha and Alonso-Ferrero, Maria and Schambach, Axel and Schambach, Axel and Baum, Christopher and Baum, Christopher and Baum, Christopher and Risma, Kimberly and Malik, Punam and Jordan, Michael and Rivat, Christine and Booth, Claire and Thrasher, Adrian and Whilding, Lynsey and Archibald, Kyra and Oberg, Daniel and Golan, Talia and Hubert, Ayala and Shemi, Amotz and Khvalevsky, Elina Zorde and Gabai-Malka, Racheli and Focht, Gili and Brunschwig, Zivia and Raskin, Stephen and Goldberg, Nahum and Ben-David, Eli and Peretz, Tamar and Eliakim, Rami and Dankur, Alan and Galun and Rachmur, Itzik and Domb, Avi and Kopelman, Yael and Hantz, Yael and Lahav, Mor and Arbel-Alon, Sagit and Dickson, George and Barkats, Martine and Daboussi, Fayza and Silva, Georges and Cedrone, Frederic and Epinat, Jean Charles and Juillerat, Alexandre and Valton, Julien and Montini, Eugenio and Biffi, Alessandra and Biffi, Alessandra and Calabria, Andrea and Calabria, Andrea and Biasco, Luca and Biasco, Luca and Cesani, Martina and Cesani, Martina and Benedicenti, Fabrizio and Benedicenti, Fabrizio and Plati, Tiziana and Leo, Simone and Zanetti, Gianluigi and Aiuti, Alessandro and ...
Human Gene Therapy, ISSN 1043-0342, 10/2012, Volume 23, Issue 10, pp. A1 - A173
Journal Article